



2497

Attorney Docket No.: UBC.P-031

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Gleave et al.
Serial No.: 10/605,498
Confirmation: 2497
Filed: October 2, 2003
Title: Compositions and methods for treatment of prostate and other solid cancers

SUBMISSION OF INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants request that the references listed on Substitute Form PTO-1449, which is enclosed, be made of record in the Patent Office file relating to the above-captioned application. Copies of the references are provided herewith.

No fee is believed to be due with this paper as we have not received an action on the merits. However, the Commissioner is authorized to charge any fees which may be due to Deposit Account Number 15-0610.

Respectfully submitted,

OPPEDAHL & LARSON LLP

Marina T. Larson

Marina T. Larson, PhD , Reg. No. 32,038
P.O. Box 5068
Dillon, CO 80435-5068
970-468-6600


CERTIFICATE OF MAILING UNDER 37 CFR §1.8(a)

I hereby certify that this paper and the attachments named herein are being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on _____

Jan 9, 2004

1-9-2004
Date of Signature

Lori South
Lori South



PTO/SB/08A (06-03)

Approved for use through 07/31/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project
Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/605,498
Filing Date	10/2/2003
First Named Inventor	Gleave et al.
Art Unit	1614
Examiner Name	
Attorney Docket Number	UBC.P-031

Sheet	1	of	2
-------	---	----	---

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of US PTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08B (06-03)

Approved for use through 06/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/605,498
Filing Date	10/2/2003
First Named Inventor	Gleave et al.
Art Unit	1614
Examiner Name	
Attorney Docket Number	UBC-P-031

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BUBENDORF ET AL., Hormone Therapy Failure in Human Prostate Cancer: Analysis by Complementary DNA and Tissue Microarrays, Journal of the National Cancer Institute, 10/20/1999, Page(s) 1758-1764, Volume 91, Number 20	
		CORNFORD ET AL., Heat Shock Protein Expression Independently Predicts Clinical Outcome in Prostate Cancer, Cancer Research, 12/15/2000, Page(s) 7099-7105, Volume 60	
		HORMAN ET AL., Anti-Sense Inhibition of Small-Heat-Shock-Protein (HSP27) Expression in MCF-7 Mammary-Carcinoma Cells Induces Their Spontaneous Acquisition of A Secretory Phenotype, Int. J. Cancer, 3/17/1999, Page(s) 574-582, Volume 82	
		OESTERREICH ET AL., The Small Heat Shock Protein hsp27 Is Correlated with Growth and Drug Resistance in Human Breast Cancer Cell Lines, Cancer Research, 10/1/1993, Page(s) 4443-4448, Volume 53	
		RICHARDS ET AL., Effect of Overexpression of the Small Heat Shock Protein HSP27 on the Heat and Drug Sensitivities of Human Testis Tumor Cells, Cancer Research, 5/15/1996, Page(s) 2446-2451, Volume 56	
		RONDEAUX ET AL., Effects of Antisense HSP27 Gene Expression in Osteosarcoma Cells, In Vitro Cell Dev. Biol. - Animal, 10/1/1997, Page(s) 655-658, Volume 33	
		WU ET AL., Expression of the 25-kDa Heat-Shock Protein (HSP27) Correlates with Resistance to the Toxicity of Cadmium Chloride, Mercuric Chloride, cis-Platinum(II)-Diammine Dichloride, or Sodium Arsenite in Mouse Embryonic Stem Cells Transfected with Sense or Antisense HSP27 cDNA, Toxicology and Applied Pharmacology, 7/18/1996, Page(s) 330-339, Volume 141	
		YAMOTO ET AL., Heat shock protein 27 was up-regulated in cisplatin resistant human ovarian tumor cell line and associated with the cisplatin resistance, Cancer Letters, 4/2/2001, Page(s) 173-181, Volume 168	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.